RU1826911C - Method of prophylaxis and treating atherosclerosis in experiment - Google Patents
Method of prophylaxis and treating atherosclerosis in experimentInfo
- Publication number
- RU1826911C RU1826911C SU904841348A SU4841348A RU1826911C RU 1826911 C RU1826911 C RU 1826911C SU 904841348 A SU904841348 A SU 904841348A SU 4841348 A SU4841348 A SU 4841348A RU 1826911 C RU1826911 C RU 1826911C
- Authority
- RU
- Russia
- Prior art keywords
- experiment
- prophylaxis
- treating atherosclerosis
- cholesterol oxidase
- cholesterol
- Prior art date
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Изобретение относитс к экспериментальной медицине. Цель изобретени - повышение эффективности терапии. Дл этого в организм орально ввод т гиполипидеми- ческое средство - холестериноксидазу в микрогранулах.The invention relates to experimental medicine. The purpose of the invention is to increase the effectiveness of therapy. For this, a lipid-lowering agent, cholesterol oxidase in microgranules, is orally administered to the body.
Description
Изобретение относитс к медицине, а именно к лекарственным средствам, оказывающим гиполипидемическое и антиатеро- склеротическое действие.The invention relates to medicine, namely to medicines having a lipid-lowering and anti-atherosclerotic effect.
Целью изобретени вл етс использование дл профилактики и лечени атеросклероза фермента микробного происхождени - холестериноксидазы путем перорального его применени .The aim of the invention is the use for the prevention and treatment of atherosclerosis of an enzyme of microbial origin - cholesterol oxidase by its oral administration.
Дл достижени гиполипидемического эффекта препарат примен ют в микрогранулах . Отличием этого способа вл етс пероральное применение холестериноксидазы в низких дозах. Препарат хорошо переноситс , побочных эффектов не наблюдаетс , изменений в органах экспериментальных животных нет.In order to achieve a hypolipidemic effect, the preparation is used in microgranules. A difference of this method is the low dose oral administration of cholesterol oxidase. The drug is well tolerated, there are no side effects, and there are no changes in the organs of experimental animals.
Изобретете иллюстрируетс следующим примером. Кролики, получающие холестерин в течение 12 дней, снижали массу тела на 220 г. Кролики, получающие вместе с холестериновой диетой перорально холе- стериноксидазу в дозе 1 - 50 ед. /кг, снижали, массу тела на 50 г. Уровень ХС-сыворотки крови у получающих холестериноксидазу на 30% ниже в сравнении с группой гиперхоле- стеринемических животных.The invention is illustrated by the following example. Rabbits receiving cholesterol for 12 days reduced their body weight by 220 g. Rabbits receiving an oral cholesterol oxidase dose of 1 to 50 units together with a cholesterol diet. / kg, reduced body weight by 50 g. The level of cholesterol-oxidizing blood serum levels is 30% lower in comparison with the group of hypercholesterolemic animals.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU904841348A RU1826911C (en) | 1990-07-10 | 1990-07-10 | Method of prophylaxis and treating atherosclerosis in experiment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU904841348A RU1826911C (en) | 1990-07-10 | 1990-07-10 | Method of prophylaxis and treating atherosclerosis in experiment |
Publications (1)
Publication Number | Publication Date |
---|---|
RU1826911C true RU1826911C (en) | 1993-07-07 |
Family
ID=21522071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU904841348A RU1826911C (en) | 1990-07-10 | 1990-07-10 | Method of prophylaxis and treating atherosclerosis in experiment |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU1826911C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010014541A3 (en) * | 2008-07-28 | 2010-11-18 | Alnara Pharmaceuticals, Inc. | Compositions and methods for treatment of hypercholesterolemia |
-
1990
- 1990-07-10 RU SU904841348A patent/RU1826911C/en active
Non-Patent Citations (1)
Title |
---|
Машковский М.Д. Лекарственные средства. Пособие по фармаколотерапии дл врачей. М,: Медицина. 1987, изд.Х, т.2, с.88- 91. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010014541A3 (en) * | 2008-07-28 | 2010-11-18 | Alnara Pharmaceuticals, Inc. | Compositions and methods for treatment of hypercholesterolemia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0706398B1 (en) | Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters | |
US3574832A (en) | Therapeutic heparin-surfactant compositions | |
RU2092183C1 (en) | Antiviral or antibacterial composition and a method of its using | |
US4734279A (en) | Combination of immunoglobulins with therapeutic agents | |
JPS62201822A (en) | Preventive and remedy for autoimmune disease | |
US3224942A (en) | Anti-inflammatory, anti-edema and anti-thrombi drug | |
RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
CA1222699A (en) | Pharmaceutical preparation for digestive ulcer | |
RU1826911C (en) | Method of prophylaxis and treating atherosclerosis in experiment | |
Minno et al. | Penicillinase in the treatment of penicillin reactions | |
WO1981001653A1 (en) | Sedative drug | |
US3574831A (en) | Therapeutic heparin-sodium taurocholate compositions | |
EP0374311A1 (en) | Urease antigen product | |
DE3688787D1 (en) | PRODUCTION OF A MEDICINE AGAINST ARTHRITIS AND RHEUMATISM. | |
RU2141819C1 (en) | Ointment with human leukocytic interferon "interon" | |
RU2219905C2 (en) | Pharmaceutical composition for vaginal administration of medicinal agent (variants), method for prophylaxis or treatment of dysmenorrhea, method for prophylaxis or treatment of premature delivery | |
AU704517B2 (en) | Anti-piroplasmotic agent | |
US5409901A (en) | Therapeutic compositions comprising nucleoproteins as the active agents, and methods of producing and using such compositions | |
RU2401112C2 (en) | Pharmaceutical composition for treating autoimmune diseases associated with increased nucleic acid antibody formation | |
US4346095A (en) | Therapeutic treatment for viral hepatitis infection | |
NL8303980A (en) | PHARMACEUTICAL PREPARATIONS WITH AN EFFECT CONTROLLING THE PHAGOCYTE FUNCTION. | |
US5942224A (en) | Therapeutic agent for cat respiratory diseases and method of treatment using the same | |
JPH0251405B2 (en) | ||
SU703087A1 (en) | Method of curing pancreatitis | |
SU1629062A1 (en) | Method for treatment of calves with colibacillosis |